However, given that insulin secretory defects seem to exist early on, even before the development of glucose abnormalities, and fasting hyperglycemia is atypical in TS, this drug may be a less appropriate first-line hyperglycemia treatment for individuals with TS. The gene discussed is INS; the disease is Hyperglycemia.